CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics is a biotech pioneer using gene-editing technology to develop potential cures for serious blood diseases and cancers.
Is CRISPR Therapeutics AG a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Leading position in cutting-edge gene-editing technology. Worth weighing: Currently not profitable with zero net margins.
What does CRISPR Therapeutics AG do?
The company uses a revolutionary tool called CRISPR to 'edit' DNA, aiming to fix genetic errors that cause life-altering illnesses. Income flows from partnering with larger pharmaceutical firms to bring these complex treatments to market, though they are still in the early stages of turning a profit. Much depends on their progress in winning regulatory approval so their therapies can reach patients.
On our factor screen it looks strongest on growth and value, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 1041% over the year
- Growth screens high
- Quality screens low
- Income screens low
Does CRISPR Therapeutics AG pay a dividend?
No - CRISPR Therapeutics AG doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
Does CRISPR Therapeutics AG have more cash or more debt?
It holds about $2.36B in cash against about $783.75M of debt - so it has net cash of about $1.58B. More cash than debt is a cushion: it does not need to borrow just to cover what it owes.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do CRISPR Therapeutics AG's numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-11. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has CRISPR Therapeutics AG actually fallen?
Over the last 2 years of daily prices, CRISPR Therapeutics AG fell as much as −43% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Who owns CRISPR Therapeutics AG?
About 81% of CRISPR Therapeutics AG, or about 81 in every 100 shares, is held by big institutions such as pension and index funds, and company insiders hold about 6%. The rest, roughly 13%, is held by the public and smaller investors.
What this does and doesn't tell you
This is a recent snapshot of the share register, and it moves. We don't read anything into who owns what - a high institutional share is common for any large listed company and is not a signal about it.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does CRISPR Therapeutics AG make?
Revenue and profit by quarter, and how much of each sale turns into profit.
When does CRISPR Therapeutics AG report earnings, and how did recent quarters go?
CRISPR Therapeutics AG is next scheduled to report on about 2026-11-09 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-08-03 | $-1.18 | $-0.94 | Beat +21% |
| 2026-05-04 | $-1.23 | $-1.28 | Missed -4% |
| 2026-02-12 | $-1.23 | $-1.37 | Missed -12% |
| 2025-11-10 | $-1.29 | $-1.17 | Beat +9% |
| 2025-08-04 | $-1.40 | $-1.29 | Beat +8% |
| 2025-05-06 | $-1.28 | $-1.58 | Missed -24% |
Across the last 6 quarters here, CRISPR Therapeutics AG came in ahead of what analysts expected 3 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for CRISPR Therapeutics AG?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
The company becomes a leader in a new era of genetic medicine.
Technological obsolescence or inability to scale production.
What are the pros and cons of CRISPR Therapeutics AG?
A balance check, not a score or verdict.
- Leading position in cutting-edge gene-editing technology
- Strong revenue growth: How fast the company's sales grew versus a year ago. trajectory
- Strategic partnerships with established pharmaceutical giants
- Currently not profitable with zero net margins
- High share price volatility compared to the broader market
- No dividend payments for shareholders
- High dependency on successful clinical trial outcomes
- Strict and unpredictable regulatory hurdles
- Significant cash burn required for ongoing research and development
The write-up's own warning lights — if these start happening, the case above changes.
- A permanent halt to clinical trials for their lead candidates
- A major shift in how gene therapies are regulated or funded globally
Common questions about CRISPR Therapeutics AG
Does CRISPR Therapeutics AG pay a dividend?
No - CRISPR Therapeutics AG does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.
When does CRISPR Therapeutics AG report earnings next?
CRISPR Therapeutics AG is next scheduled to report results on about 2026-11-09. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
Intuitive Surgical, Inc.
BioNTech SE
Hims & Hers Health, Inc.
Intellia Therapeutics, Inc.
Novavax, Inc.
Smith & Nephew
Bristol-Myers Squibb Company
Align Technology, Inc.Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.